[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometriosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometriosis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,172,0,25,[9,44,73,117,145,172,196,222,247,271,298,323,349,376,405,433,450,473,495,522,546,562,582,605,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100406082","comparison-of-proton-or-intensity-modulated-radiation-therapy-after-surgery-for-endometrial-or-cervical-cancer-100406082",false,"NCT04567771","Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer","A Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity-Modulated Radiation Therapy for Post-Operative Treatment of Endometrial or Cervical Cancers","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of cervical or endometrial cancer\n* Must have undergone an open or robotic hysterectomy (total abdominal, vaginal, radical, or total laparoscopic) for carcinoma of the cervix or endometrium\n* History and physical prior to registration\n* Documentation of history of:\n\n  * Smoking status\n  * Pelvic infection\n  * Pelvic inflammatory disease\n  * Endometriosis\n* Planned to receive either proton or IMRT radiation treatment, with use of rectal balloon, at any Mayo Clinic site\n* Plan for RT to pelvis with or without para-aortic lymph node irradiation\n* If received high-dose chemotherapy prior to registration, last dose must have been given \\>= 21 days prior to start of RT\n* Complete blood count (CBC) performed within 21 days prior to registration\n* Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)\u002FCT, or PET\u002FMRI for staging before registration; may be pre-operative (op) or post-op\n* Eastern Cooperative Oncology Group (ECOG) performance score 0-2\n* Provide written informed consent\n* Willing to complete quality of life (QOL) questionnaires\n\nExclusion Criteria:\n\n* Receiving external beam boost dose during RT\n* Distant metastases\n* Gross disease at time of RT\n* Histology of endometrial stromal sarcoma, leiomyosarcoma, melanoma or small cell carcinomas\n* Patients who exceed the weight\u002Fsize limits of the treatment table\n* Positive or close surgical margins (=\\\u003C 3 mm)\n* Prior RT to the pelvis\n* Planned to receive inguinal node RT\n* Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note that human immunodeficiency virus (HIV) testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be immunosuppressive.\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years\n* Severe, active co-morbidity defined as follows:\n\n  * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n* Other major medical illness which requires hospitalization or precludes study therapy at the time of registration\n* Patients unwilling to have rectal balloon placed on a daily basis during RT","FEMALE","18 Years",{"count":20,"type":21},121,"ESTIMATED","INTERVENTIONAL",[24],"NA","This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors. Using quality of life questionnaires and adverse event assessments may help doctors learn whether proton radiation therapy is associated with lower acute gastrointestinal toxicities at the end of treatment compared to intensity modulated radiation therapy in patients with endometrial or cervical cancer.",[27,28,29,30],"Cervical Carcinoma","Endometrial Carcinoma","Endometriosis","Pelvic Inflammatory Disease","RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-19","ACTUAL",{"date":37,"type":35},"2020-12-04",{"date":39,"type":21},"2029-04-01",{"name":41,"class":42},"Mayo Clinic","OTHER",3,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100652600","deep-endometriosis-affecting-the-urogenital-tract-long-term-outcomes-and-impact-on-renal-function-100652600","NCT07776574","Deep Endometriosis Affecting the Urogenital Tract: Long-term Outcomes and Impact on Renal Function","RENDO","Inclusion Criteria:• age ≥ 18 years;\n\n* hydronephrosis caused by DE-related ureteral stenosis;\n* for Group F: a history of surgical treatment of ureteral endometriosis (ureterolysis, ureteroureterostomy, UCNA) at our center at least 24 months previously;\n* for Group S: indication for surgical treatment because of hydronephrosis or clinically significant ureteral stenosis;\n* signed informed consent.\n\nExclusion Criteria:• pregnancy;\n\n* malignancy;\n* congenital uropathy;\n* other renal diseases;\n* inability to undergo dynamic renal scintigraphy (e.g., allergy to the radiopharmaceutical or severe comorbidities precluding the examination);\n* previous urinary tract surgery unrelated to ureteral endometriosis that could substantially confound the assessment of renal function.",{"count":52,"type":21},20,"36 Months","OBSERVATIONAL","Endometriosis is a chronic estrogen-dependent disease characterized by the presence and growth of endometrium-like tissue outside the uterine cavity.\n\nThis ectopic endometrial tissue induces a chronic local and systemic inflammatory response, resulting in the most common manifestations of the disease: chronic pelvic pain, infertility, and pelvic adhesions. In deep endometriosis (DE), adhesions and infiltrative growth may damage adjacent organs.\n\nOverall, endometriosis affects approximately 10% of women of reproductive age. Its prevalence is higher among women with infertility (20-50%) and among patients with chronic pelvic pain (up to 90%).\n\nThe disease is usually categorized as superficial peritoneal, ovarian, or deep endometriosis (DE). Deep endometriosis is a progressive form of the disease that may affect organs beyond the pelvic cavity, including the urinary tract, alter their anatomy, and cause functional impairment.\n\nUrogenital involvement occurs in approximately 1-5.5% of all women with endometriosis; the prevalence is substantially higher among patients with DE, reaching 16-53% according to the available literature.\n\nWithin the urinary tract, the bladder is most commonly affected (70-85%), followed by the ureters (9-23%), kidneys (approximately 4%), and urethra (approximately 2%).\n\nUreteral endometriosis is therefore a relatively rare but clinically significant entity. It may be unilateral or bilateral, with a predominance of left-sided involvement.\n\nTwo basic forms are distinguished:\n\n* \"Extrinsic\" - ureteral stenosis caused by periureteral fibrosis and the presence of DE lesions without infiltration of the ureteral wall.\n* \"Intrinsic\" - ureteral stenosis caused by direct infiltration of the ureteral wall by endometriotic tissue.\n\nUreteral stenosis causes secondary hydronephrosis and, unless treated in a timely manner, may lead to a progressive loss of renal function.\n\nThe disease frequently remains asymptomatic for a prolonged period. Up to half of cases are diagnosed incidentally or only at an advanced stage, when renal damage is already irreversible.\n\nEarly detection and timely planning of surgical management are therefore essential for preserving renal function.\n\nThe main surgical procedures are:\n\n* ureterolysis - release of the ureter from fibrotic adhesions, preferred for the extrinsic form;\n* ureteroneocystostomy (UCNA) - indicated for the intrinsic form when the affected segment must be resected and the ureter reimplanted into the bladder;\n* ureteroureterostomy (ureteral anastomosis) - appropriate for the intrinsic form when, following resection, the distal ureteral segment is sufficiently long to allow anastomosis of healthy margins.\n\nDespite the clinical significance of the condition, prospective studies objectively evaluating the evolution of renal function after the individual types of surgical management of ureteral endometriosis are still lacking.\n\nA modern diagnostic strategy combining specialized ultrasound, dynamic renal scintigraphy (MAG3), and analysis of urinary biomarkers of tubular injury (KIM-1, CCL-2, L-FABP) enables earlier detection of renal dysfunction and more accurate monitoring of postoperative recovery. Identification of sensitive biomarkers of early renal injury and validation of an algorithm for their use could substantially improve decisions regarding the timing of surgery and subsequent postoperative follow-up.\n\nBased on our experience, some patients surgically treated for hydronephrosis caused by DE-related ureteral stenosis show persistent morphological changes on renal ultrasound and the manifestation of systemic conditions such as arterial hypertension during long-term follow-up. To date, no study has focused on the long-term follow-up of patients with ureteral DE and its potential consequences. The expected benefit of this study is to establish clear criteria for the indication of surgical treatment of ureteral endometriosis and to develop an evidence-based protocol for long-term follow-up.",[29,57,58],"Endometriosis (Diagnosis)","Urinary Tract Diseases",[60,61,62],"deep infiltrated endometriosis","ureteral endometriosis","nephrectomy","2026-08-17",{"date":65,"type":35},"2026-08-20",{"date":67,"type":35},"2026-04-01",{"date":69,"type":21},"2029-07-01",{"name":71,"class":42},"Charles University, Czech Republic",1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":54,"phases":4,"briefSummary":84,"conditions":85,"keywords":94,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":72},"100652437","prospective-perioperative-clinical-registry-for-women-undergoing-benign-gynecological-surgery-100652437","NCT07772076","Prospective Perioperative Clinical Registry for Women Undergoing Benign Gynecological Surgery","Prospective Observational Registry on the Collection of Perioperative Clinical Data in Gynecology","OPGYNBEN","Inclusion Criteria:\n\n1. Age \\>= 18 years\n2. Diagnosis of benign gynecological disease (e.g., uterine fibroids, endometriosis, pelvic neoplasm, endometrial polyp, endometrial hyperplasia, cervical dysplasia, pelvic adhesions, isthmocele, genital prolapse, adenomyosis, female genital malformations, pelvic inflammatory disease)\n3. Indication for elective benign gynecological surgery\n4. Signed written informed consent for data collection\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Suspected or confirmed malignant gynecological disease\n3. Current pregnancy\n4. Emergency \u002F unscheduled surgical procedure\n5. No indication for surgery\n6. Refusal or inability to provide signed informed consent",{"count":82,"type":21},6000,"3 Years","This prospective observational registry aims to systematically collect preoperative, intraoperative, and postoperative clinical data from patients undergoing surgery for benign gynecological conditions. The main goal is to evaluate clinical outcomes, surgical approaches, and complications in real-world clinical practice.",[86,87,29,88,89,90,91,92,93],"Benign Gynecological Disease","Uterine Fibroids","Adenomyosis","Pelvic Adhesions","Ovarian Cyst Benign","Salpingitis","Polyp Endometrium","Ectopic Pregnancy",[95,96,97,98,99,100,101,102,103,104,105,106,107,108],"Gynecological Surgery","Perioperative Data","Laparoscopy","uterine fibroids","endometriosis","Registry","Uterine Myoma","Pelvic Pain","Surgical Outcomes","Hysteroscopy","Laparotomy","Perioperative Care","Postoperative Complications","Real-World Evidence","NOT_YET_RECRUITING",{"date":34,"type":35},{"date":112,"type":21},"2026-09",{"date":114,"type":21},"2039-09",{"name":116,"class":42},"IRCCS San Raffaele",{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100651837","perioperative-yoga-therapy-and-endometriosis-surgery-100651837","NCT07765680","Perioperative Yoga Therapy and Endometriosis Surgery","The Effectiveness of Yoga Therapy on Chronic Pain, Endometriosis Symptoms and Quality of Life Following Surgery for Endometriosis","YOGENDOCHIR","* Adult woman (18 years or older) covered by a social health insurance scheme.\n* Surgery for endometriosis is indicated.\n* No assisted reproductive technology (ART) protocol planned within 6 months after surgery.\n* No chronic pain attributable to another disease or condition.\n* No yoga practice outside the study during participation.",{"count":126,"type":21},188,[24],"YOGENDOCHIR is a multicentre, prospective, randomised, controlled, parallel-group study involving 188 adult women scheduled to undergo surgery for endometriosis.\n\nThe study compares standard surgical management alone with the same management combined with a structured perioperative yoga therapy programme comprising 32 guided sessions (16 before and 16 after surgery), supplemented by a secure digital platform supporting independent practice and adherence monitoring.\n\nThe primary objective is to assess the effect of yoga therapy on endometriosis-related pain, as measured by the pain subscale of the Endometriosis Health Profile-30 (EHP-30). Participants are assessed before surgery and at 3, 6, and 12 months after the procedure.\n\nSecondary outcomes include quality of life, pain characteristics, fatigue, sleep, anxiety and depressive symptoms, sexual health, kinesiophobia, activities of daily living, medication use, healthcare utilisation, absenteeism, adherence, satisfaction, and the participants' ability to use the platform independently.",[29,130,131],"Chronic Pain","Impairment of Quality of Life",[29,133,134,135],"chronic pain","yogatherapy","surgery","2026-08-10",{"date":138,"type":35},"2026-08-14",{"date":140,"type":21},"2026-10-01",{"date":142,"type":21},"2029-10-01",{"name":144,"class":42},"University Hospital, Lille",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100651192","endoexpedition---use-of-a-serious-game-to-deliver-patient-information-and-decision-aid-for-individuals-with-endometriosis-100651192","NCT07758946","Endoexpedition - Use of a Serious Game to Deliver Patient Information and Decision Aid for Individuals With Endometriosis.","Endoexpedition - Use of a Serious Game to Deliver Patient Information and Decision Aid for Individuals With Endometriosis: A National Multicenter Randomized-controlled Trial.","Inclusion Criteria:\n\n* Age 18 years or older.\n* Suspected or confirmed endometriosis.\n* Able to understand written Swedish.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Inability to independently complete the Swedish-language educational game.\n* Unwillingness or inability to provide informed consent.",true,{"count":154,"type":21},250,[24],"Endometriosis is a chronic disease that can negatively affect quality of life, daily functioning, fertility, and psychological well-being. Adequate patient education is important for informed decision-making and active participation in care, but traditional written information may not meet the needs of all patients.\n\nThis national multicenter randomized controlled trial will evaluate whether a serious game can improve patient satisfaction when delivering information about endometriosis and its treatment options compared with standard written information. Adults with suspected or confirmed endometriosis will be randomized to receive either game-based educational material (Endoexpedition) or traditional written information. The study will assess patient satisfaction, knowledge acquisition, engagement, knowledge retention, and user interaction with the educational platform. A total of 250 participants will be included and followed for up to one year.",[29],[29,159,160,161,162],"Serious game","Patient information","Digital Education","Decision Support",{"date":164,"type":35},"2026-08-11",{"date":166,"type":21},"2026-09-01",{"date":168,"type":21},"2029-09",{"name":170,"class":42},"Karolinska Institutet",4,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":195},"100617443","phase-3-evaluate-the-efficacy-and-safety-of-hmi-115-in-women-with-moderate-to-severe-endometriosis-associated-pain-100617443","NCT07318688","Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain","A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension","Inclusion Criteria:\n\n* 1\\. Premenopausal female subjects, between 18 and 49 years of age, inclusive.\n* 2\\. Has a surgical diagnosis of endometriosis (laparoscopy or laparotomy) as documented by medical records within 10 years before screening.\n* 3\\. Has a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 at screening with a score of at least 2 for DYS and at least 2 for NMPP.\n* 4\\. Subject has reported \"moderate\" or \"severe\" for her endometriosis-associated DYS AND NMPP before randomization.\n* 5\\. Subject has at least two consecutive regular menstrual cycle (i.e. 21 to 35 days in duration) prior to randomization.\n* 6\\. Subject agrees to use required (nonhormonal) birth control methods during the entire length of participation in the study and agrees to avoid pregnancy from signing the informed consent until 12 weeks after the last dose.\n* 7\\. Subject agrees to use only those rescue analgesic medications permitted by the protocol during the Screening, Treatment and Posttreatment follow-up Periods for her endometriosis-associated pain.\n* 8\\. Criteria for Extension Treatment Period：Subject who completes treatment of the placebo-controlled double-blind treatment period and assessments at Week 24.\n\nExclusion Criteria:\n\n* 1\\. Subject who is pregnant or breastfeeding or is planning a pregnancy during the study period or is less than 6 months post-partum or 3 months post-abortion at the time of entry into the Screening Period or pregnancy before randomization.\n* 2\\. Subject has an intra-uterine device (IUD). Subject is eligible if she removes the IUD 1 month before screening.\n* 3\\. Subject has chronic pelvic pain that is not caused by endometriosis (e.g., interstitial cystitis, irritable bowel syndrome) or has any other chronic pain syndrome (e.g., fibromyalgia, chronic back pain, myofascial pain syndrome, chronic headaches) that requires chronic analgesic or other chronic therapy, which would interfere with the assessment of endometriosis-associated pain.\n* 4\\. Subject with a current history of undiagnosed abnormal genital bleeding.\n* 5\\. Subject with history of hysterectomy and\u002For bilateral oophorectomy.\n* 6\\. Subject has had surgery for endometriosis within 6 weeks prior to entry into the Screening Period.\n* 7\\. Subject has previous history of a severe, life-threatening or other significant sensitivity to any opioids or non-steroidal anti-inflammatory drugs (NSAIDS) or any contraindication to their use such as gastrointestinal ulcer or bleeding.\n* 8\\. Subject with known hypersensitivity to any of the IMP ingredients.\n* 9\\. Subject has an estimated glomerular filtration rate (eGFR) of \\\u003C 60mL\u002Fmin\u002F1.73 m2 at Screening Period.\n* 10\\. Subject is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 30 days prior to the start of Screening Period or 5 half-lives, whichever is longer.\n* 11\\. Subject who has been exposed to HMI-115 treatment.\n* 12\\. Subject has used medications such as hormones, analgesics, medications associated with bone loss, products that affect PRL levels, etc. within specific time window before Screening.\n* 13\\. Subject has clinically significantly abnormal laboratory tests at Screening Period, including:\n\n  1. Alanine transaminase (ALT\u002FSGPT), or aspartate aminotransferase (AST\u002FSGOT) ≥200% of the upper limit of normal, or total bilirubin (unless known diagnosis of Gilbert's syndrome) ≥ 150% of the upper limit of normal range.\n  2. Hemoglobin \\\u003C 100 g\u002FL, Neutrophil count \\\u003C 1.5×109\u002F L, Platelet count \\\u003C 100×109\u002F L.\n* 14\\. Subject has clinically significantly abnormal laboratory tests at Screening Period, including: Neutrophil count \\\u003C 1.5×109\u002F L, Platelet count \\\u003C 100×109\u002F L.\n* 15\\. Subject has clinically significant abnormal ECG, or ECG with QTcF \\> 450 msec at Screening Period.\n* 16\\. Subject has a history or current has malignancy except for treated basal cell carcinoma and cutaneous squamous cell carcinoma of the skin.\n* 17\\. Subject is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the study.\n* 18\\. Subject has any of the following conditions within the last 6 months before Screening:\n\n  1. Myocardial infarction, stroke, unstable angina or transient ischemic attack.\n  2. Classified as being in New York Heart Association Class III or IV.\n* 19\\. Subjects with body weight greater than 300 pounds or 136 kilograms.\n* 20\\. Any other conditions in the Investigator's opinion that prevent the subject from participating.\n* 21\\. Criteria for Extension Treatment Period： Subjects entering the follow-up period after treatment: subjects with a BMD decrease of ≥ 8.0% or Z-value ≤ -2.0 in any part of the lumbar spine, femoral neck, or total hip compared to baseline.","49 Years",{"count":181,"type":21},540,[183],"PHASE3","A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension",[29],"2026-08-09",{"date":164,"type":35},{"date":189,"type":35},"2026-01-29",{"date":191,"type":21},"2028-09-01",{"name":193,"class":194},"Hope Medicine (Nanjing) Co., Ltd","INDUSTRY",5,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100650955","phase-ia-trial-of-hhk001-compared-with-enantone-in-patients-with-endometriosis-100650955","NCT07755956","Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis","A Phase Ia Clinical Trial to Compare Pharmacokinetics, Pharmacodynamics, Safety and Preliminary Efficacy of HHK001 Versus Enantone in Patients With Endometriosis","Inclusion Criteria:\n\n* Voluntarily provide written informed consent;\n* Female, aged 18-45 years, weight ≥ 40 kg, body mass index 19-28 kg\u002Fm²;\n* The most recent menstrual cycle 21-35 days;\n* Confirmed diagnosis of endometriosis, and suitable for GnRH agonist;\n* Cervical cytology test result showing No Intraepithelial Lesion or Malignancy;\n* No plan for pregnancy, egg cryopreservation or donation, and agree to use effective contraception from screening through 3 months after dosing.\n\nExclusion Criteria:\n\n* Allergic to GnRH agonists\u002Fantagonists, or history of allergies to ≥3 different substances, or active allergic disease;\n* With contraindications to rescue medication (ibuprofen);\n* Current or past medical history of osteoporosis\u002Fosteopenia, pituitary tumor, epilepsy, depressive disorder, thromboembolic events, malignant tumors, unexplained abnormal uterine bleeding;\n* Received any GnRH agonist\u002Fantagonist within 12 weeks before screening;\n* Received medications that may significantly alter hypothalamic-pituitary-gonadal axis hormone levels within 4 weeks before screening;\n* History of miscarriage within 4 weeks before screening;\n* History of alcohol dependence, drug abuse or illicit substance use;\n* Other conditions unsuitable for the trial judged by the investigator.","45 Years",{"count":205,"type":21},30,[207],"PHASE1","The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check how the body absorbs and responds to each medicine, monitor possible side effects and treatment benefits.\n\nResearchers will compare HHK001 to Enantone to test the advantages of its updated formulation.",[29],[211,212,213,99],"leuprorelin","pharmacokinetics","pharmacodynamics","2026-08-06",{"date":136,"type":35},{"date":217,"type":21},"2026-08-31",{"date":219,"type":21},"2027-03-31",{"name":221,"class":194},"Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":228,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":72},"100650531","guangdong-provincial-endometriosis-clinical-research-cohort-100650531","NCT07749053","Guangdong Provincial Endometriosis Clinical Research Cohort","Inclusion Criteria:\n\n* Inclusion Criteria:\n\nFemale participants aged 18 to 45 years. Able and willing to provide written informed consent. For the endometriosis cohort: diagnosis of endometriosis based on clinical findings, imaging, and\u002For laparoscopy.\n\nFor the endometriosis cohort: availability of complete baseline clinical data, including revised American Society for Reproductive Medicine stage and lesion type.\n\nFor the healthy control cohort: healthy women matched by age and body mass index to participants in the endometriosis cohort.\n\nFor the healthy control cohort: regular menstrual cycles of 28 to 30 days.\n\nExclusion Criteria:\n\nFor the endometriosis cohort: concurrent malignant tumor or severe cardiac, hepatic, or renal disease.\n\nFor the endometriosis cohort: previous hysterectomy. For the endometriosis cohort: a mental disorder that prevents adherence to study follow-up.\n\nExclusion Criteria:\n\n\\-",{"count":229,"type":21},716,"Endometriosis is a chronic condition that may cause pelvic pain, ovarian cysts, infertility, and recurrent symptoms. This prospective observational cohort study will enroll women aged 18 to 45 years with endometriosis and age- and body mass index-matched healthy women. Participants will receive routine clinical care, and the study will not assign medications or procedures. Baseline clinical information will be collected, and participants will be followed for 24 months, every 3 months during the first year and every 6 months thereafter. The study will assess cyst recurrence, pain recurrence, pregnancy and live birth outcomes, and other long-term clinical outcomes. It will also evaluate associations between disease characteristics, rASRM stage, routine medical treatment, and subsequent clinical and reproductive outcomes, and will support the establishment of an endometriosis clinical research database.",[29],[233,234,102,235,236,237,238],"Prospective Cohort","Ovarian Endometrioma","Disease Recurrence","Pregnancy Outcome","Live Birth","Infertility","2026-08-01",{"date":214,"type":35},{"date":242,"type":35},"2026-02-02",{"date":244,"type":21},"2029-07",{"name":246,"class":42},"Li Li",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":254,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":72},"100647876","biomarkers-for-endometriosis-100647876","NCT07713797","Biomarkers for Endometriosis","A Prospective, Observational and Multicentric Study to Evaluate the Performance and Clinical Utility of EndoID ELISA Kit to Determine Circulating Synuclein Gamma (SNCG) and B-cell Lymphoma-6 (BCL6) Levels as Potential Biomarkers for Endometriosis\"","Inclusion Criteria for Endometriosis Group:\n\n* Women of reproductive age group (18Y-45Y).\n* Women with active endometriosis diagnosed by ultrasound\u002FMRI\u002Flaparoscopy.\n\nExclusion Criteria for Endometriosis Group:\n\n* Women \\\u003C18Y and \\>45Y.\n* Women with endometriosis during stimulation with gonadotropins.\n* Current or prior history of uterine, ovarian, colon, pancreatic, breast or any other type of cancer.\n* Any prior history of chronic illness.\n* Pregnant women.\n\nInclusion Criteria for Control Group:\n\n* Women of reproductive age group (18Y-45Y).\n* Women without endometriosis and any other gynaecological problem.\n\nExclusion Criteria for Endometriosis Group:\n\n* Women \\\u003C18Y and \\>45Y\n* Prior history of any disease including cancer or chronic illness.\n* Pregnant women.",{"count":255,"type":21},100,"Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and infertility. Currently, endometriosis can only be definitively diagnosed through invasive procedures like laparoscopy and biopsy.\n\nThe purpose of this study is to investigate whether the proteins Synuclein Gamma (SNCG) and B-Cell Lymphoma 6 (BCL6), measurable in blood and menstrual fluid, can serve as non-invasive biomarkers to diagnose or monitor endometriosis.",[29],[99,259,260,261],"biomarkers","BCL6","SNCG","2026-07-30",{"date":264,"type":35},"2026-08-03",{"date":266,"type":35},"2026-01-16",{"date":268,"type":21},"2027-09-01",{"name":270,"class":42},"Trio Fertility",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":279,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":72},"100649131","improving-access-to-pelvic-health-physiotherapy-for-endometriosis-100649131","NCT07731776","Improving Access to Pelvic Health Physiotherapy for Endometriosis","Optimizing Care and Improving Access to Pelvic Health Physiotherapy for Women Living With Endometriosis: A Portrait of the Current Situation and Recommendations for Possible Solutions in Quebec (Canada)","ENDO-RM","Inclusion Criteria (part 1):\n\n* Female (biological sex at birth)\n* Aged between 18 and 45 years old\n* Residing in the province of Quebec, Canada\n* Able to speak and understand French\n* Has a confirmed or suspected diagnosis of endometriosis\n\nInclusion Criteria (part 2):\n\n* Licensed physiotherapist authorized to practice pelvic health physiotherapy in Quebec, Canada\n* Currently practicing in the province of Quebec, Canada\n* Provides pelvic health physiotherapy services to women experiencing symptoms associated with endometriosis\n\nInclusion Criteria (part 3):\n\nWomen living with endometriosis:\n\n* Female (biological sex at birth)\n* Aged between 18 and 45 years old\n* Residing in the province of Quebec, Canada\n* Able to speak and understand French\n* Has a confirmed or suspected diagnosis of endometriosis\n\nHealthcare providers\u002Fmanagers:\n\n\\- Has experience providing, coordinating, organizing or managing care for women with confirmed or suspected endometriosis in the province of Quebec, Canada",{"count":280,"type":21},264,"This is a mixed-methods study aimed to generate new evidence to help optimize access to pelvic health physiotherapy (PHPT) for women living with endometriosis in the province of Quebec (Canada). Specifically, the objectives are to:\n\nObj. 1: Understand the patient journey of women living with endometriosis, including their experiences accessing PHPT.\n\nObj. 2: Describe current PHPT clinical practices and service delivery for women living with endometriosis in Quebec.\n\nObj. 3: Identify barriers, facilitators and potential strategies to improve access to PHPT services and optimize the patient journey of women living with endometriosis in Quebec.\n\nFindings will inform clinical, organizational and policy recommendations to strengthen the integration of PHPT within multidisciplinary endometriosis care. The project is divided into three sequential parts:\n\nPart 1: Semi-structured individual interviews (open-ended questions) will be conducted with women living with endometriosis to explore their journey to obtain endometriosis care, experiences accessing PHPT and perceived barriers and facilitators. Approximately 15-20 participants will be recruited until data saturation is reached.\n\nPart 2: An online cross-sectional survey will be conducted among pelvic health physiotherapists practicing in the province of Quebec, Canada to describe current clinical practices, service delivery and challenges related to the management of women living with endometriosis. The minimum expected sample size is 225 physiotherapists .\n\nPart 3: Semi-structured focus groups (open-ended questions) will be conducted with women living with endometriosis, pelvic health physiotherapists, physicians and healthcare managers to identify and prioritize strategies to improve access to PHPT services. Approximately 24-32 participants will be recruited across four focus groups.\n\nAcross all three parts, recruitment strategies will aim to ensure diversity in participant characteristics, including geographic region, sociodemographic characteristics and healthcare experiences, to capture a broad range of perspectives.",[29],[284,285,29,286,287,288,289],"Women's Health","Chronic Pelvic Pain","Patient Navigation","Delivery of Health Care","Healthcare Access","Pelvic Health","2026-07-29",{"date":262,"type":35},{"date":293,"type":35},"2026-07-28",{"date":295,"type":21},"2027-03-29",{"name":297,"class":42},"Université de Sherbrooke",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":72},"100625987","identify-a-specific-immune-profile-in-patients-with-chronic-pelvic-pain-resistant-to-first-line-treatments-by-measuring-th1-th2-th17-and-treg-cytokines-produced-after-non-specific-functional-cell-stimulation---immunocpp-100625987","NCT07429773","Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP","ImmunoCPP","Inclusion Criteria:\n\n1. Aged between 18 and 40;\n2. Under continuous hormone treatment for at least 6 months;\n3. Imaging less than 12 months old: either normal or showing endometriosis and\u002For adenomyosis lesions, excluding any other abnormalities that could explain the PCOS;\n4. Affiliation with the French Social Security system;\n5. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Autoimmune disease;\n3. History of cancer within the last 5 years or currently undergoing treatment;\n4. Current infectious syndrome;\n5. Person under guardianship or conservatorship.","40 Years",{"count":307,"type":21},120,[24],"Chronic pelvic pain (CPP) affects more than one in four women. An immune imbalance in the Th1\u002FTh2 balance has been reported in multiple CPP situations, particularly in patients with endometriosis, but with mixed results. The use of a functional immune test, already validated in previous indications and particularly in infertility, could simulate an immune stimulation similar to that of painful attacks.",[29,311],"Chronic Pelvic Pain Syndrome",[29,311,313],"women","2026-07-24",{"date":316,"type":35},"2026-07-27",{"date":318,"type":35},"2026-04-14",{"date":320,"type":21},"2028-04",{"name":322,"class":42},"Centre Hospitalier Universitaire de Nice",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":72},"100444615","early-phase-1-endometriosis-and-microvascular-dysfunction-role-of-inflammation-100444615","NCT05069740","Endometriosis and Microvascular Dysfunction: Role of Inflammation","Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis","Endo3\u002FSA2","Inclusion Criteria:\n\n* Healthy women between the ages of 18 and 45 years (Controls), taking oral contraceptive or with regular menses every 26-34 days\n* Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \\\u003C5 years prior, and reported by the subject to the researchers)\n* Tylenol if the subject has acute pain is allowed\n* Contraceptive use is allowed\n\nExclusion Criteria:\n\n* Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)\n* Diabetes (HbA1C 6.5%)\n* BP\\>140\u002F90\n* Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)\n* Pregnancy\n* Breastfeeding\n* Taking illicit and\u002For recreational drugs\n* Abnormal liver function\n* Rash, skin disease, disorders of pigmentation, known skin allergies\n* Diagnosed or suspected metabolic or cardiovascular disease\n* Persistent unexplained elevations of serum transaminases\n* Known allergy to latex or investigative substances (including salsalate or simvastatin)\n* History of gastrointestinal bleeding",{"count":332,"type":21},24,[334],"EARLY_PHASE1","The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction.\n\nEpidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.",[29],[338,339,340,341],"skin blood flow","inflammation","Lectin-like oxidized LDL receptor (LOX-1)","intradermal microdialysis",{"date":316,"type":35},{"date":344,"type":35},"2022-01-01",{"date":346,"type":21},"2026-12-31",{"name":348,"class":42},"Penn State University",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":72},"100649279","pelvic-floor-physical-therapy-and-exercise-for-women-with-endometriosis-and-chronic-pelvic-pain-100649279","NCT07733583","Pelvic Floor Physical Therapy and Exercise for Women With Endometriosis and Chronic Pelvic Pain","Pelvic Floor Physical Therapy and Physical Exercise Versus Placebo for the Treatment of Endometriosis With Chronic Pelvic Pain: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female, aged 18 to 45 years.\n* Diagnosis of endometriosis confirmed by surgery and\u002For imaging examinations.\n* Chronic pelvic pain for at least 6 months.\n* Visual Analog Scale (VAS) score ≥4 for chronic pelvic pain.\n* Willingness and ability to provide written informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Current pregnancy or planned pregnancy during the study period.\n* Pelvic surgery within the previous 3 months.\n* Neuromodulation treatment within the previous 3 months.\n* Medical or musculoskeletal conditions that contraindicate participation in pelvic floor physical therapy or the exercise program.",{"count":357,"type":21},64,[24],"Endometriosis is a chronic gynecological condition that can cause persistent pelvic pain, painful menstruation, painful sexual intercourse, and reduced quality of life. This study will evaluate whether specialized pelvic floor physical therapy combined with a structured physical exercise program is more effective than a placebo intervention combined with the same exercise program in reducing chronic pelvic pain in women with endometriosis. Participants will be randomly assigned to one of the two groups and followed for 12 weeks.",[29,285],[362,285,29,363,364,365,366,367],"Pelvic Floor Physical Therapy","Randomized Controlled Trial","Physical Exercise","Quality of Life","Dyspareunia","Dysmenorrhea","2026-07-23",{"date":290,"type":35},{"date":371,"type":35},"2026-03-05",{"date":373,"type":21},"2027-09-30",{"name":375,"class":42},"Hospital de Clinicas de Porto Alegre",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":384,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":72},"100648926","phase-1-assessing-the-mechanisms-and-impact-of-a-novel-cannabinoid-product-for-gynecologic-pain-100648926","NCT07728695","Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain","PAIN-GP: Project Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain","PAIN-GP","Inclusion Criteria:\n\n* Provides informed consent\n* Sex assigned female at birth\n* Capable of having menstrual cycles\n* Aged 21+\n* Endorses one of the following gynecologic pain conditions: endometriosis, adenomyosis, chronic pelvic inflammatory disease (PID)\n* Stable medication\u002Fpsychotherapy regimens for at least 3 months prior to starting the study, including hormonal contraceptives\n\nAdditional inclusion criteria for those in the PK subgroup:\n\n* Willingness to participate in the PK procedures (i.e., agree to an indwelling catheter with repeated blood collection)\n\nExclusion Criteria:\n\n* Meets criteria for DSM-5 classification of current substance use disorder, psychotic disorder, bipolar disorder, or an eating disorder\n* Currently uses cannabinoid products\n* Positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding\n* Presence of a serious or unstable medical illness, including liver\u002Fkidney disease, cardiovascular disease, neurological disorder, and conditions or medications that impact drug absorption or gastric emptying (e.g., GLP-1 agonists)\n* Comorbid neuropathic pain or cancer-related pain\n* Disclosure of a genetic polymorphism affecting CYP2C9 function\n* Liver function test (LFT) values \\>3x the upper limit of normal (ULN) at the baseline visit","21 Years",{"count":386,"type":21},60,[207,388],"PHASE2","Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals living with endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID), will identify specific targets and mechanisms underlying the potential impact of a hemp-derived, full-spectrum, high-CBD product in individuals with gynecologic pain.",[29,88,391],"Chronic Pelvic Inflammatory Disease",[393,394,395,99,396,397],"cannabidiol","gynecologic pain","cannabinoid","adenomyosis","pelvic inflammatory disease","2026-07-22",{"date":316,"type":35},{"date":112,"type":21},{"date":402,"type":21},"2029-01",{"name":404,"class":42},"Staci Gruber, Ph.D.",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":72},"100616393","pelvic-pain-electro-acupuncture-100616393","NCT07305025","Pelvic Pain Electro-Acupuncture","Pelvic Pain Electro-Acupuncture: Randomized Study for Symptom Liberation","PEARL","Inclusion Criteria:\n\n* Women aged 18-45 years referred for diagnostic laparoscopy with suspicion of endometriosis\n* Experiencing moderate to severe pelvic pain\n* Willing to commit to the treatment schedule and follow-up\n* Understanding Norwegian or English to be able to communicate and fill out questionnaires\n\nExclusion Criteria:\n\n* Pregnancy\n* Use of opioid pain relief\n* Concurrent participation in other pain management trials",{"count":414,"type":21},38,[24],"The aim of the study is to investigate if a series of up to 9 treatment sessions of electroacupuncture can be used to alleviate pain in women with suspected endometriosis, scheduled for diagnostic laparoscopy",[102,29],[419,99,420,421,422,423],"pelvic pain","acupuncture","sexual function","quality of life","pelvic floor muscle function","2026-07-17",{"date":426,"type":35},"2026-07-21",{"date":428,"type":35},"2025-12-16",{"date":430,"type":21},"2027-04-30",{"name":432,"class":42},"St. Olavs Hospital",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":384,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":72},"100552770","phase-2-evaluating-the-impact-of-a-novel-cannabinoid-product-for-endometriosis-100552770","NCT06477406","Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis","Inclusion Criteria:\n\n1. Subject has provided informed consent\n2. Sex assigned female at birth\n3. Subject is 21 or older\n4. Subject is fluent in English\n5. Subject endorses at least moderate levels of pain at the baseline visit\n6. Subject endorses having endometriosis\n\nExclusion Criteria:\n\n1. Non-fluent English speakers\n2. Endorsement of current substance use disorder, psychotic disorder, or an eating disorder\n3. Currently uses cannabis or cannabinoid products regularly\n4. Patients will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding\n5. Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper\u002Fhypotension, cardiac disorders), or neurological disorder (including seizure disorder)\n6. Neuropathic pain or cancer-related pain\n7. Disclosure of a genetic polymorphism affecting CYP2C9 function",{"count":205,"type":21},[388],"Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.",[29],{"date":426,"type":35},{"date":445,"type":35},"2024-02-27",{"date":447,"type":21},"2026-10",{"name":449,"class":42},"Mclean Hospital",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":72},"100629004","impact-of-surgery-for-deep-posterior-endometriosis-on-ovarian-reserve-endoro-100629004","NCT07469007","Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve (ENDORO)","Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve","ENDORO","Inclusion Criteria:\n\n* Female, aged 18 to 39 years old;\n* Suspected severe deep posterior pelvic endometriosis on reference pelvic MRI (ovarian kissing, obliteration of the pouch of Douglas) with concordant clinical examination, or confirmed severe deep posterior pelvic endometriosis during exploratory laparoscopy;\n* Patient affiliated with or covered by a social security plan;\n* Patient having been informed and having given her free, informed, and written consent\n\nExclusion Criteria:\n\n* Presence of ovarian involvement defined by the presence of at least one endometrioma \\>5 mm;\n* History of surgery for severe deep endometriosis;\n* Severe preoperative premature ovarian insufficiency (defined by AMH \\\u003C1ng\u002FmL and antral follicle count \\\u003C8);\n* Concurrent use of GnRH agonist therapy at or within the preceding 3 months of enrollment;\n* BMI \\>35 kg\u002Fm²;\n* Menopausal status;\n* Patient participating in another trial with an exclusion period that has not yet expired at the time of screening;\n* Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision;\n* Pregnant, breastfeeding, or postpartum woman.","39 Years",{"count":255,"type":21},[24],"Endometriosis is a chronic condition typically affecting women of reproductive age and often responsible for chronic pelvic pain and\u002For infertility.\n\nIts prevalence is estimated at 10% of the female population. Deep endometriosis is a specific phenotype of the disease, defined histologically by infiltration of the peritoneum exceeding 5 mm or by fibromuscular plaques infiltrating the muscularis propria of the abdominopelvic organs. It affects approximately 12 to 20% of patients with endometriosis.\n\nSurgery is one of the treatment options. Its aim is anatomical restoration, notably through complete macroscopic resection of the lesions and the release of adhesions, particularly those affecting the adnexa. While the negative impact of cystectomies on ovarian reserve is well known, the impact of surgery for severe deep endometriosis without ovarian involvement has never been studied. Yet, these procedures are regularly performed, and in the vast majority of cases on women of reproductive age. Moreover, the impression gathered in routine practice suggests a decrease in reserve parameters of around 5%. Therefore, understanding the actual impact of the procedure on ovarian reserve would, if it were concrete, allow for expanding the indications for preoperative fertility preservation to this subgroup of patients.\n\nThe main objective is to evaluate the impact of complete macroscopic resection of severe deep posterior pelvic endometriosis on the change in AMH levels at 12 months compared to an unexposed group.",[29,463],"Ovarian Reserve","2026-07-15",{"date":466,"type":35},"2026-07-16",{"date":468,"type":35},"2025-02-11",{"date":470,"type":21},"2028-02-11",{"name":472,"class":42},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":493,"locationsCount":72},"100647846","pelvic-floor-muscle-function-and-endometriosis-related-pelvic-pain-100647846","NCT07713108","Pelvic Floor Muscle Function and Endometriosis-Related Pelvic Pain","Pelvic Pain and Pelvic Floor Muscle Function in Women With Endometriosis: Preliminary Findings From a Pilot Feasibility Case-Control Study","Inclusion Criteria:\n\n* Women aged 18-50 years of reproductive age with self-reported endometriosis will be included in the study group, while women aged 18-50 years of reproductive age who are gynecologically healthy and report no history of endometriosis will be included in the control group. Additional inclusion criteria include adequate proficiency in the Hungarian language, access to the internet, and provision of informed consent.\n\nExclusion Criteria:\n\n* Exclusion criteria include lack of capacity to provide informed consent, severe physical or cognitive impairment, pregnancy, postpartum period, diagnosed malignant disease, or the presence of vaginal infection or inflammation.","48 Years",{"count":255,"type":21},"Our study aims to investigate the associations between endometriosis-related pelvic pain and pelvic floor muscle strength, endurance, and relaxation ability, as well as quality of life, physical activity, and the presence of pelvic floor symptoms. Furthermore, it aims to assess the function of muscles synergistic with the pelvic floor in comparison with healthy controls.",[29,285,484],"Pelvic Pain Associated With Endometriosis or Adenomyosis",[29,419,486,487],"pelvic floor muscle","manometry","2026-07-14",{"date":490,"type":35},"2026-07-20",{"date":67,"type":35},{"date":191,"type":21},{"name":494,"class":42},"University of Pecs",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":508,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":72},"100647622","histological-assessment-of-tissue-penetration-depth-of-argon-beam-coagulation-in-ovarian-endometriomas-100647622","NCT07711743","Histological Assessment of Tissue Penetration Depth of Argon Beam Coagulation in Ovarian Endometriomas","Histological Assessment of Tissue Penetration Depth of Argon Beam Coagulation in Ovarian Endometriomas: A Prospective Pilot Study","ENDO-ARGON","Inclusion Criteria:\n\n* Female patients aged 18-40 years.\n* Indication for surgical treatment of ovarian endometrioma based on clinical symptoms and\u002For imaging findings.\n* Diagnosis of ovarian endometrioma ≥3 cm confirmed by preoperative imaging (ultrasound and\u002For MRI).\n* Planned laparoscopic cystectomy.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Expected lack of compliance or inability to understand the study procedures.\n* Previous surgical procedures on the affected ovary.\n* Recurrent ovarian endometrioma.\n* Pregnancy or breastfeeding.\n* Participation in another interventional clinical study that may influence study outcomes, such as anti-Müllerian hormone (AMH) levels or pregnancy.",{"count":504,"type":21},50,[24],"The goal of this clinical trial is to evaluate the depth of tissue penetration of Argon Beam Coagulation (ABC) during laparoscopic surgery for ovarian endometriomas. Researchers want to determine how deeply ABC affects ovarian tissue and to generate data on the safety of this surgical technique.\n\nParticipants will undergo standard laparoscopic surgery for ovarian endometriomas. During the planned surgical procedure, Argon Beam Coagulation will be applied to the ovarian surface according to the study protocol. The treated tissue will subsequently be excised as part of the planned surgery and analyzed histologically to measure the depth of tissue penetration.",[234,29],[509,234,29,97,510,511,512,513,463],"Argon Beam Coagulation","Histopathology","Tissue Penetration","Ovarian Cystectomy","Fertility Preservation","2026-07-13",{"date":424,"type":35},{"date":517,"type":35},"2026-07-09",{"date":519,"type":21},"2027-08-07",{"name":521,"class":42},"Insel Gruppe AG, University Hospital Bern",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":152,"sex":17,"minAge":530,"maxAge":203,"enrollmentInfo":531,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":72},"100576425","endometriosis-and-migraine-100576425","NCT06785129","Endometriosis and Migraine","Mechanisms Underlying Endometriosis and Migraine Comorbidity","EMC","Inclusion Criteria:\n\n1. Patients with diagnosed endometriosis, migraine, or both endometriosis and migraine\n2. Healthy control subjects with no history of chronic pain\n3. Age 12-45\n4. Assigned female sex at birth\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Presence of prolactinoma\n3. Presence of psychiatric, neurological, endocrinological and\u002For developmental conditions and taking medications for these conditions\n4. Current use of dopamine agonist or SSRI medications\n5. For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health","12 Years",{"count":307,"type":21},"This study aims to determine differences in experimental pain and sex hormone levels between patients with migraine, patients with endometriosis, patients with migraine and endometriosis, and healthy controls. Participants will complete surveys, experimental pain paradigms and collection of samples for hormone analyses.",[534,29],"Migraine",[534,99,536,537],"hormones","pain","2026-07-10",{"date":514,"type":35},{"date":541,"type":35},"2025-02-12",{"date":543,"type":21},"2030-01-01",{"name":545,"class":42},"Washington University School of Medicine",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":530,"maxAge":203,"enrollmentInfo":553,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":72},"100523868","endometriosis-pain-100523868","NCT06101303","Endometriosis Pain","The Mechanisms Underlying Endometriosis Pain","Inclusion criteria:\n\n* Patients with pelvic pain with and without endometriosis scheduled for an operative laparoscopic surgery for endometriosis diagnosis and\u002For treatment\n* Age 12-45\n* Females\n\nExclusion criteria:\n\n* Pregnancy\n* Planned hysterectomy or oophorectomy\n* Co-occurring vaginismus and\u002For vulvodynia\n* For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health",{"count":307,"type":21},"Aim 1. To determine the factors contributing to pain in patients with chronic pelvic pain with and without endometriosis Aim 2. To determine the changes following endometriosis lesion removal surgery in pain and sex hormone levels.\n\nAim 3. To identify factors predicting clinical pain reduction after lesion removal surgery.\n\nAdditional exploratory aims might compare subgroups of patients such as patients with vs. without endometriosis, with vs. without additional chronic pain syndromes, and with vs. without hormonal treatment. In addition, the role of lesion-specific immune signatures and psychological factors on pain will be explored.\n\nPatients with pelvic pain potentially due to endometriosis will complete questionnaires including social, health, behavioral, and psychological questionnaires. Patients will also complete a 2.5 hours study visit of psychophysical assessments of thermal and pressure stimuli. In addition, blood, urine, and saliva samples will be collected for hormonal, immune, and genetic analyses. Additional samples might be collected and stored for future analyses. For some participants, these procedures will be completed several times, including before the surgery as well as 3 months, 6 months and 1 year after surgery. After the surgery, surveys assessing pain and other symptoms will be sent every week on the first month and then monthly for 1 year. In addition, during the surgery, biopsies will be collected and analyzed to determine hormonal, immune and genetic factors.\n\nFor adolescents, a parent\u002Flegal guardian will be asked to assist in completing some of the health-related surveys (i.e., physical developmental survey, health survey, migraine history survey).",[102,29],{"date":514,"type":35},{"date":558,"type":35},"2023-09-29",{"date":560,"type":21},"2029-09-01",{"name":545,"class":42},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":72},"100646376","expression-of-target-in-endometriotic-lesions-100646376","NCT07693283","Expression of Target in Endometriotic Lesions","To Investigate the Expression of Target in Endometriotic Lesions","Inclusion Criteria:\n\n* Pathologically confirmed endometriosis via laparoscopy and histopathological examination\n* Complete clinical and pathological data available\n\nExclusion Criteria:\n\n• History of any malignant tumor","50 Years",{"count":571,"type":21},40,"Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide. This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis. The investigators will compare the expression levels of these molecules between endometriotic lesions and normal tissue. The primary objective of this study is to elucidate the potential roles of these molecules in the pathogenesis of endometriosis.",[29],"2026-07-08",{"date":517,"type":35},{"date":577,"type":35},"2026-04-13",{"date":579,"type":21},"2027-02-12",{"name":581,"class":42},"Beijing Tsinghua Chang Gung Hospital",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":72},"100646943","study-on-the-self-administered-use-of-a-specialized-kit-for-the-management-of-sexual-pain-associated-with-endometriosis-100646943","NCT07683468","Study on the Self-Administered Use of a Specialized Kit for the Management of Sexual Pain Associated With Endometriosis","Single-Center, Controlled, Randomized Study on the Self-Administered Use of a Specialized Kit for the Management of Sexual Pain Associated With Endometriosis","KIT-ENDO-SEXO","Inclusion Criteria:\n\n* Women aged 18 to 45\n* Sexually active within the past 3 months\n* Confirmed diagnosis of endometriosis\n* Pain during sexual intercourse, as reported by the patient\n* Patients enrolled in or covered by the French social security system.\n* Patients who have been informed and have provided their free, informed, and written consent (no later than the day of enrollment and prior to any examination required for the study).\n\nExclusion Criteria:\n\n* Patients participating in another interventional clinical trial for endometriosis.\n* Pregnant, breastfeeding, or laboring women\n* Patients who do not speak French or are unable to provide informed consent for the study\n* Patients with an allergy to any component of the study kit\n* Individuals who do not have a touchscreen mobile phone compatible with the Endo Doute app.\n* Participants whose physical and\u002For psychological health is severely impaired, which, in the investigator's opinion, may affect the participant's compliance with the study.\n* Participants currently in the exclusion period of another ongoing study at the time of enrollment.\n* Protected participants: adults under guardianship, conservatorship, or other legal protection; or individuals deprived of their liberty by judicial or administrative order.",{"count":255,"type":21},[24],"Endometriosis is a complex gynecological condition that affects approximately 10% of women of reproductive age, according to 2023 data from the World Health Organization. Endometriosis is often associated with debilitating pain, particularly during sexual intercourse (dyspareunia). This pain profoundly affects these patients' sexual health and, consequently, their quality of life, yet it remains frequently misunderstood and inadequately managed, partly due to a lack of information and appropriate tools.\n\nOne of the key aspects of this study is the use of the Sexual Activity Questionnaire (SAQ), an internationally recognized assessment tool for measuring the impact of treatment on sexual functioning. The SAQ collects precise data on sexual activity (primarily frequency), the level of sexual pleasure, and the perceived pain potential experienced by patients during sexual activity, assessing not only the intensity of pain but also its influence on the emotional and relational aspects of intimate life. The SAQ has been validated to assess the impact of surgical treatments for endometriosis on sexual functioning.\n\nThe results obtained through this questionnaire in routine clinical practice formed the basis for the tools developed by Dr. Magalie Benoit, providing an in-depth understanding of the different types of pain experienced by patients.\n\nThe kit used in the study contains:\n\n1. The Endo-Sexo Guide: A 258-page book that compiles and analyzes possible responses to the SAQ. It explains in detail the mechanisms of sexual pain and offers personalized solutions to alleviate it.\n2. The Endo Doute app: It allows women to keep a journal tracking pain (frequency and intensity), the frequency of sexual intercourse, and the tools used to relieve pain (including those provided in the kit). It also allows users to export their data to share with the healthcare professionals involved.\n3. A set of practical tools for managing sexual pain on a daily basis, including an endo-vaginal TENS device to treat dyspareunia, penis rings to limit deep penetration, hyaluronic acid suppositories, CBD (cannabinoid) lubricant gel, sublingual CBD oil to reduce stress, as well as two dietary supplements-one containing palmitoylethanolamide (PEA) to combat inflammation and the other made from herbs to aid menstrual comfort.\n\nThese tools will be used independently by patients, offering them personalized solutions to better understand and manage their pain on their own. Each patient will be able to choose whether or not to use the various components of the kit and how often to use them. Empowering patients to manage their own pain should improve their sexual quality of life and reduce the need for occasional or unscheduled medical care.\n\nThis project represents the first initiative aimed at evaluating the impact of these tools on patients' autonomy in managing sexual pain related to endometriosis.",[29],[595,99,537],"sexual health","2026-07-02",{"date":598,"type":35},"2026-07-06",{"date":600,"type":35},"2026-05-29",{"date":602,"type":21},"2027-06",{"name":604,"class":42},"Elsan",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":619,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":72},"100646805","ovarian-reserve-after-laparoscopic-cystectomy-for-endometriotic-and-non-endometriotic-cysts-100646805","NCT07686783","Ovarian Reserve After Laparoscopic Cystectomy for Endometriotic and Non-Endometriotic Cysts","Ovarian Reserve After Laparoscopic Cystectomy for Endometriotic and Non-Endometriotic Cysts: A Comparative Prospective Cohort Study","Inclusion Criteria:\n\n* Female patients aged 18-45 years\n* Ovarian cyst measuring 6-15 cm in diameter, confirmed by transvaginal ultrasound or MRI\n* Cyst is persistent for more than 3 months if asymptomatic, OR any symptomatic cyst regardless of duration of diagnosis\n* Serum anti-Müllerian hormone (AMH) level ≥ 2 ng\u002FmL, measured within 1 month preoperatively\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Clinical or ultrasonic suspicion of ovarian malignancy\n* Ovarian cyst associated with pregnancy\n* Previous history of ovarian surgery\n* History of pelvic irradiation or chemotherapy\n* Known endocrine disorders affecting ovarian function (e.g., PCOS, premature ovarian insufficiency, thyroid dysfunction, hyperprolactinemia)\n* Current use of hormonal contraceptives or hormonal therapy within 3 months prior to enrollment\n* Presence of severe systemic disease that contraindicates surgery or general anesthesia\n* Refusal to participate or inability to provide informed consent",{"count":386,"type":21},[24],"We will conduct this study to estimate the effect of laparoscopic cystectomy on ovarian reserve in endometriotic cysts versus non-endometriotic cysts.",[616,29,617,463,618],"Ovarian Cysts","Benign Ovarian Cyst","Cystectomy",[97,618,620,621,622],"Endometriotic Ovarian Cysts","Benign Ovarian Cysts","Ovarian Reserve Markers",{"date":624,"type":35},"2026-07-07",{"date":626,"type":21},"2026-06-30",{"date":628,"type":21},"2027-09",{"name":630,"class":42},"Benha University",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":641,"conditions":642,"keywords":647,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":72},"100645235","crest-samphire-guided-care-program-on-wellbeing-work-productivity-and-quality-of-life-100645235","NCT07679074","CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life","A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions","CREST","Inclusion Criteria:\n\n* Self-identified female, aged 18-65 years at the time of enrollment\n* Basic English literacy\n* Able and willing to provide informed consent electronically\n* Residing in the United States\n* Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)\n* Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships\n* Currently in full-time employment with medical benefits as part of compensation package\n* Access to a smartphone with internet access compatible with the Samphire mobile application\n* Able to safely operate the study device in the home environment\n* Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or actively planning pregnancy during the study period\n* History of epilepsy or seizure disorder\n* Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation\n* Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use\n* Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use\n* Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening\n* Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening\n* Inability to provide informed consent or safely use the device in the home environment\n* Current participation in another interventional neurotechnology or drug study","65 Years",{"count":504,"type":21},"This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program\n\n* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.",[643,644,367,29,645,646,102],"Premenstrual Syndrome","Premenstrual Dysphoric Disorder","Perimenopause","Menopause",[648,649,650,651,652,653,654,655,656,657,658,659,660,661,662],"tDCS","neuromodulation","hormonal health","menstrual symptoms","perimenopause","menopause","PMDD","PMS","work productivity","brain fog","mood","cognitive function","digital health","decentralized clinical trial","guided care","2026-06-25",{"date":665,"type":35},"2026-07-01",{"date":667,"type":35},"2026-06-01",{"date":669,"type":21},"2027-03-01",{"name":671,"class":194},"Samphire Group, Inc."]